Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

So compounded semaglutide is sold in a vial with a separate syringe. Compounding drugs isn’t a new practice. But due to the soaring demand for these weight loss drugs ... or through patients [sharing ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

At the least, the new 7.2mg results point to scope for hiking the semaglutide dose in CagriSema to chase down that weight-loss target. The company is also running a phase 3b trial of 7.2mg ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...